Kronos Bio Appoints Elena Ridloff, CFA, to Board of Directors

SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced that the company has appointed Elena Ridloff, CFA, to its Board of Directors, where she will serve as Chair of the Audit Committee. Ms. Ridloff brings nearly 20 years of experience in the biopharmaceutical sector, serving in senior leadership positions in corporate finance and investor relations, including a decade spent as an institutional investor covering the healthcare industry.

“Elena is a seasoned executive with deep financial and biopharma industry experience, including working with commercial stage companies,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “This expertise, coupled with her strong relationships with the financial community, will be valuable as we advance our lead programs into later-stage clinical development and build awareness of our proprietary product discovery engine, focused on dysregulated transcription factors, and its potential to generate a pipeline of novel oncology candidates.”

Ms. Ridloff currently serves as the Executive Vice President, Chief Financial Officer for ACADIA Pharmaceuticals Inc. She joined the company in April 2018 as Senior Vice President, Investor Relations, where she led investor and financial communications activities. Before joining ACADIA, Ms. Ridloff was Vice President of Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee, where she built and led the investor relations function and played a key role in broadening and strengthening the shareholder base.

“I am honored to join Kronos’ board during this exciting time in the company’s development,” said Ms. Ridloff. “I look forward to working with Kronos’ management and Board to capitalize on our robust clinical pipeline and advance our discovery programs towards the clinic.”

Prior to her role as an industry executive, Ms. Ridloff was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors in her role as a Managing Director at Maverick Capital, a hedge fund based in New York. She also was a senior analyst at Paramount Capital, an investment firm focused on the biotechnology sector. Ms. Ridloff also previously served as Chief Executive Officer of BIOVISIO, an independent consulting firm serving the life sciences industry. Ms. Ridloff earned her B.A. in history and sociology of science from the University of Pennsylvania. She is also a CFA® charterholder.

About Kronos Bio, Inc.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

For more information, please visit www.kronosbio.com or follow the company on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005304/en/

Investor Contact:
Dr Yasir Al-Wakeel
CFO & Head of Corporate Development
[email protected]

Media Contact:
Sheryl Seapy
W2O pure
+1 213-262-9390
[email protected]

Source: Kronos Bio, Inc.

You May Also Be Interested In

• Irvine Center of Innovation & Entrepreneurship Approved by City Council
• FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
• Maple Agro Farms Corporation Announces Letter of Intent to Acquire 50-Year Renewable Leasehold Interest Covering Approximately 10,000 Acres of Agricultural Land in Ghana